Document:

EX-10.13

  Exhibit 10.13

   

  THIS SECOND AMENDMENT AGREEMENT (the "Amendment") is made on March 7, 2022 (the "Amendment Date")

  BETWEEN

  (1)Sanquin Blood Supply Foundation, a non-profit organization, with offices located at Plesmanlaan 125, 1066 CX Amsterdam, the Netherlands ("Sanquin"); and 

  (2)Gemini Therapeutics Sub, Inc., formerly Gemini Therapeutics Inc., a corporation organized under the laws of Delaware, having a place of business at One Kendall Square, Building 300, Floor 3,. Cambridge MA 02139 ("Gemini")

  Sanquin and Gemini are hereinafter jointly also referred to as the “Parties” and individually as a “Party".

  RECITALS

  (A)The Parties entered into a Research Collaboration and License Agreement dated 1 April 2017 as subsequently amended on April 29, 2018 (the “Original Agreement”).

  (B)The Parties wish to amend and supplement certain provisions of the Original Agreement as set out in this Amendment.

  AGREED TERMS

   

  1.Definitions and Interpretation

  1.1In this Amendment, including the Recitals, terms defined in the Original Agreement will have the same meaning when used in this Amendment. In addition, in this Amendment:

  (a)“Second Patent Application” shall mean International Application No. PCT/NL2019/050018 filed on January 15, 2019, together with (i) all patents which may be granted pursuant to the foregoing, (ii) all reissues, extensions (including patent term adjustments and supplementary protection certificates (or the equivalent thereof)), renewals, substitutions, confirmations, registrations, re-registrations, restorations, re-examinations, continuations, continuations-in-part, divisions, and patents of addition, with respect to the foregoing; and (iii) all patent applications and patents which claim priority from or common priority with the foregoing; and

  (b)“Third Patent Application” shall mean International Application No. PCT/US2020/042627 filed on July 17, 2020, together with (i) all patents which may be granted pursuant to the foregoing, (ii) all reissues, extensions (including patent term adjustments and supplementary protection certificates (or the equivalent thereof)), renewals, substitutions, confirmations, registrations, re-registrations, restorations, re-examinations, continuations, continuations-in-part, divisions, and 

   

   

  

   

  patents of addition, with respect to the foregoing; and (iii) all patent applications and patents which claim priority from or common priority with the foregoing.

  1.2Except as otherwise provided in this Amendment, the terms of the Original Agreement  shall remain in full force and effect provided that in the event of a conflict or ambiguity between the terms of the Original Agreement and the terms of this Amendment, the terms of this Amendment shall prevail.  

  2.Supplement to Original Agreement

  2.1The Parties hereby acknowledge and agree, notwithstanding any provision of the Original Agreement:

  (a)The Third Patent Application shall be jointly owned by the Parties;

  (b)Gemini shall have the exclusive right to prepare and file the Third Patent Application at Gemini’s discretion and expense (and Sanquin shall not take any action in connection with the same); 

  (c)Gemini will have the first right (but not the obligation) to prosecute and maintain the Third Patent Application and shall use counsel reasonably acceptable to Sanquin for such activities. Gemini will provide to Sanquin all patent office papers promptly upon receipt, and drafts of responses to office actions from and other substantive filings with any patent office regarding the Third Patent Application sufficiently in advance before their submission to enable review and comment by Sanquin, and Gemini will consider in good faith all comments made by Sanquin. If Gemini chooses not to continue with the prosecution and maintenance of any patent right within the Third Patent Application, Gemini will notify Sanquin of such decision at least ninety (90) days before any such patent right would become forfeited or abandoned, and Sanquin will have the right (but not the obligation) to prosecute and maintain the relevant patent right(s) within the Third Patent Application provided that Sanquin will provide to Gemini all patent office papers promptly upon receipt, and drafts of responses to office actions from and other substantive filings with any patent office regarding the relevant patent right(s) sufficiently in advance before their submission to enable review and comment by Gemini, and Sanquin will consider in good faith all comments made by Gemini;

  (d)The provisions of clauses 7.2 and 7.3 of the Original Agreement shall apply equally to the Third Patent Application (including following termination of the Original Agreement).

  (e)Subject to clause 2.1(f) of this Amendment, Sanquin hereby grants to Gemini and its Affiliates an exclusive (even as to Sanquin however with the exception under clause 2.1(f)) worldwide license, with the right to sublicense through multiple tiers, under the Third Patent Application for all purposes in all fields, provided that such sub-licences will honour and follow provisions in this Amendment.

  (f)Gemini hereby grants to Sanquin a non-exclusive, fully paid-up, non-transferable:

  2

   

  

   

  (i)non-sublicensable, licence under the Third Patent Application solely for the purpose of performing its obligations under the Research Plan;

  (ii)license to use and permit other non-profit research institutions to use the Third Patent Application for educational and non-clinical research purposes provided that such third parties are not granted any rights to sell or commercialize products or services within the scope of the Third Patent Application.  

  (g)In the event of termination of the Original Agreement prior to expiry of the Third Patent Application:

  (i)the provisions of clauses 2.1(a) to 2.1(d)of this Amendment shall continue to apply until expiry of the Third Patent Application (unless otherwise mutually agreed by the Parties in writing);

  (ii)the provisions of clauses 2.1(e) and 2.1(f) of this Amendment shall terminate and each Party shall have (and to the extent necessary hereby grants and agrees to grant to the other) a fully paid-up, non-exclusive, worldwide, perpetual, irrevocable, transferable license, with the right to sublicense through multiple tiers, under the Third Patent Application for all purposes in all fields; in all cases without any obligation to account to the other Party.

  (h)The Third Patent Application shall be deemed to be included within “Research Program Patent Right” and “Research Program Intellectual Property” for the purposes of the following clauses of the Original Agreement: 3, 4.4(c), 4.5 and 8.3 and in addition:

  (i)1.16 (definition of “Licensed Product”) and all instances in which such defined term is used in the Original Agreement; 

  (ii)1.19 (definition of “Non-Royalty Sublicense Income”) and all instances in which such defined term is used in the Original Agreement;

  (iii)1.32 (definition of “Sanquin Intellectual Property”) and all instances in which such defined term is used in the Original Agreement; and

  (iv)1.36 (definition of “Valid Claim”) and all instances in which such defined term is used in the Original Agreement; and

  (i)The Third Patent Application shall be deemed not to be included within “Research Program Patent Right” or “Research Program Intellectual Property” for the purposes of the following clauses of the Original Agreement: 2.1(b), 4.3(b), 7.1, 8.1, 8.4, and 10.3.

  2.2With effect from 1 April 2017 clause 10.4 of the Original Agreement shall be deemed to be deleted and replaced with the following:

  3

   

  

   

  “Termination or expiration of this Agreement will not affect the rights and obligations of the Parties accrued prior to termination hereof. The provisions of Section 4.9 Section 10.2 and this Section 10.4, Article 1, entitled Definitions; Article 3, entitled Term of Agreement; Article 7, entitled Intellectual Property; Article 8.2(b) entitled Sublicensing Terms and Article 8.5, entitled No Implied Rights; Article 9, entitled Confidentiality, Publication, Use of Name; Article 11, entitled Warranties, Indemnification; Article 12, entitled Dispute Resolution; and Article 13, entitled Additional Provisions will survive any such termination or expiration.”

  2.3With effect from April 29, 2018, the definition of “Research Program Patent Rights” shall be deemed to include, without limitation, the Second Patent Application.  

  2.4The Parties acknowledge and agree that, at all times prior to the Amendment Date, Gemini has complied with all of its obligations under clause 6.1 of the Original Agreement and Sanquin does not have any right to terminate the Original Agreement for any breach of clause 6.1 of the Original Agreement prior to the Amendment Date.

  3.General

  3.1The provisions of clause 12 of the Original Agreement shall apply equally to disputes of any nature arising under, relating to, or in connection with this Amendment.

  3.2The provisions of clause 13 of the Original Agreement shall apply equally to this Amendment (and references to ‘hereunder’ or ‘this Agreement’ or similar shall include a reference to this Amendment and its provisions).

  3.3Each Party agrees to execute, acknowledge, and deliver all such further instruments, and do all such further similar acts, as may be necessary or appropriate to carry out the purpose and intent of this Amendment.

  Agreed by the Parties through their authorized signatories:

   

  Sanquin Blood Supply Foundation	Gemini Therapeutics Sub, Inc.

  	 

   

   

  Signature:	/s/ Gerald de Haan	Signature:	/s/ Brian Piekos

  Name: 	Gerald de Haan	Name:	Brian Piekos

  Title: 	Director Research	Title:            Chief Financial Officer

  	  

   

  4Exhibit 10.1

 

KAIVAL BRANDS INNOVATIONS GROUP, INC.

2020 STOCK AND INCENTIVE COMPENSATION PLAN

 

Nonqualified Stock Option

 

Grant of Option. KAIVAL
BRANDS INNOVATIONS GROUP, INC., a Delaware corporation (the “Company”), hereby grants to the Awardee named below a Nonqualified
Stock Option for the purchase of up to but not exceeding the number of shares of the Company’s Common Stock, $.001 par value per
share (the “Option”), exercisable at the price and upon the terms and conditions set forth below, and subject to any adjustments
made pursuant to Section 14 of the Company’s 2020 Stock and Incentive Compensation Plan (“Plan”):

 

	 	Awardee:	 	 
	 	 	 	 
	 	Number of Shares:	 	 
	 	 	 	 
	 	Grant Date:	 	 
	 	 	 	 
	 	Exercise Price/Share:	 	 
	 	 	 	 
	 	Expiration Date:	 	 

 

Approval of Counsel Required
for Issuance of Common Stock. No shares of Common Stock shall be issued pursuant to the exercise of the Option unless counsel for
the Company shall be satisfied that such issuance will be in compliance with applicable Federal and state securities laws.

 

Option Subject to Plan.
The Option is granted as a Nonqualified Stock Option as defined in Section 2(w) of the Plan that is not intended to qualify as
an incentive stock option within the meaning of Section 422 of the Internal Revenue Code, is issued pursuant to the Plan, and is in all
respects subject to the terms, provisions, conditions and restrictions of the Plan. In the event of any conflict between this instrument
and the Plan, the Plan shall control.

 

Defined Terms. Except as
otherwise defined herein, capitalized terms used in this instrument shall have the meanings ascribed to such terms in the Plan.

 

Exercise Price. The Option
exercise price set forth above for each related Common Share is not less than the Fair Market Value of each Common Share calculated as
of the date of grant in accordance with Section 2(t) of the Plan. The exercise price is subject to adjustment pursuant to Section 14 of
the Plan.

 

     

     

    

 

Vesting of Option. The
Option will become vested and exercisable with respect to the number of shares set forth in the vesting schedule below until the Option
is 100% vested, except as otherwise provided in the Plan:

  

	DATE VESTED
AND	NUMBER of
SHARES
	EXERCISABLE	EXERCISABLE
	[Date]	[number]
	[Date]	[number]
	[Date]	[number]
	[Date]	[number]
	[Date]	[number]
	[Date]	[number]

 

Option Period. The Option,
or any part thereof, may be exercised at any time between the date at which it becomes vested and exercisable and the Expiration Date
set forth above, inclusive of such dates, except that in the event of the Awardee’s death, or his or her Disability (as defined
under Section 2(p) of the Plan), or if the Awardee’s employment by the Company is terminated for any reason, or if there is a Change
of Control of the Company, then the provisions of Sections 12(c) and 14(b) of the Plan, respectively, shall govern the option period.
Notwithstanding the foregoing, in no event may the Option vest and be exercised unless and until the Company has an effective Registration
Statement on Form S-8 (or such other applicable form) on file with the Securities and Exchange Commission to register the issuance of
the shares Common Stock upon the exercise of the Option, unless the Company determines that such grant (i) shall be registered in another
manner under the Securities Act of 1933, as amended (the “Securities Act”), or (ii) does not require registration under the
Securities Act in order to comply with the requirements of the Securities Act, if applicable.

 

Method of Exercise. The
Option is exercisable by providing a written notice of exercise in accordance with the procedures adopted by the Committee, but subject
to all conditions and restrictions set forth in the Plan, and the Option consideration shall be payable in one of the forms permitted
under Section 8(f) of the Plan, as determined by the Committee. The exercise price for the number of shares exercised under the Option
shall be payable in full at the time of exercise.

 

Transferability. The Option
is not assignable or transferable except by will or the laws of descent or distribution and is exercisable during the Awardee’s
lifetime only by him or her. No assignment or transfer of the Option, or the rights represented thereby, whether voluntary or involuntary,
by operation of law or otherwise (except to a designated beneficiary, upon death, by will or the laws of descent or distribution) will
vest in the assignee or transferee any interest or right herein whatsoever, but immediately upon such assignment or transfer the Option
will terminate and become of no further effect.

 

Tax Withholding on Exercise.
Awardee shall satisfy the Company’s withholding obligation of any federal, state, local or foreign taxes of any kind required to
be withheld as a result of an exercise of the Option by providing payment of the amount of such withholding: (i) by cash, certified or
cashier’s check, money order or personal check; (ii) by delivery of shares of the Company’s common stock already owned by
Awardee; (iii) by the Company’s withholding from other compensation payable to Awardee by the Company; or (iv) pursuant to a request
by Awardee, by withholding from the shares of common stock to be delivered upon exercise of the Option no more than the maximum number
of shares that is necessary to satisfy the statutory withholding obligation.

 

    Page 2 of 3

     

    

 

	KAIVAL
BRANDS INNOVATIONS GROUP, INC.	 	 	 
	 	 	 	 	 
	By:	 	 	Date:	 
	 	 	 	 	 
	Title:	 	 	 	 

 

The Awardee acknowledges receipt
of a copy of the Plan, represents that he or she is familiar with the terms and provisions thereof, and hereby accepts the Option evidenced
hereby subject to all the terms, provisions, conditions and restrictions of the Plan. The Awardee also understands that this Option is
not intended to qualify as an Incentive Stock Option as defined in Section 422 of the Code. Accordingly, the Awardee understands
that he or she will recognize taxable income upon exercise of the Option based on the difference between the Option exercise price and
the Fair Market Value of the shares at the time of exercise.

 

	Signature:	 	 
	 	 	 
	Printed Name:	 	 
	 	 	 
	Date:	 	 

 

Page 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]